Semaglutide fails in phase II trial within fatty liver disease

Novo Nordisk joins a string of other companies in acknowledging that a fatty liver can be hard to treat. On Wednesday, the company reports that its NASH therapy has failed in a phase II study as a monotherapy against the disease.

Photo: POOL New/REUTERS / X80003

Non-alcoholic fatty liver disease, also known as NASH, has proven itself to be somewhat of a headache for several companies trying to develop treatments for the disease, and Novo Nordisk might be the latest addition to the group.

On Wednesday, the Danish pharmaceutical company announced that it has completed a 48-week long phase II trial of its molecule semaglutide as a treatment for NASH. The candidate was incapable of demonstrating an effect on the disease, though that the drug was well-tolerated by patients with the serious end-stage NASH complication, cirrhosis.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs